Synaptogenix EPS - Earnings per Share 2020-2025 | TAOX
Synaptogenix eps - earnings per share from 2020 to 2025. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Synaptogenix Annual EPS |
| 2024 |
$-10.99 |
| 2023 |
$-29.56 |
| 2022 |
$-20.25 |
| 2021 |
$-62.75 |
| 2020 |
$-300.75 |
| 2019 |
$-75.25 |
| Synaptogenix Quarterly EPS |
| 2025-03-31 |
$0.04 |
| 2024-12-31 |
$-4.82 |
| 2024-09-30 |
$-4.58 |
| 2024-06-30 |
$-1.18 |
| 2024-03-31 |
$-0.41 |
| 2023-12-31 |
$12.54 |
| 2023-09-30 |
$-0.84 |
| 2023-06-30 |
$-34.67 |
| 2023-03-31 |
$-6.59 |
| 2022-12-31 |
$15.75 |
| 2022-09-30 |
$-10.75 |
| 2022-06-30 |
$-13.50 |
| 2022-03-31 |
$-11.75 |
| 2021-12-31 |
$-10.00 |
| 2021-09-30 |
$-11.75 |
| 2021-06-30 |
$-14.50 |
| 2021-03-31 |
$-26.50 |
| 2020-12-31 |
$0.00 |
| 2020-09-30 |
$-22.50 |
| 2020-06-30 |
$-58.25 |
| 2019-12-31 |
$0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.012B |
$0.000B |
|
Synaptogenix Inc. is an emerging biopharmaceutical company. It focused on developing therapies for neurodegenerative diseases. The company's lead therapeutic candidate consist Bryostatin-1. Synaptogenix Inc. is based in NEW YORK.
|
